Does the APOB rs1367117 GG genotype indicate higher LDL-C and apoB-containing particle burden?

The APOB rs1367117 variant is a well-studied polymorphism within the gene encoding apolipoprotein B, the essential structural protein for all atherogenic lipid particles. Evidence consistently links this genetic locus to variations in circulating lipid levels, suggesting that the GG genotype may influence an individual's overall atherogenic burden.

Clinical and genomic associations

Research across diverse cohorts, particularly Asian populations, has established a correlation between the rs1367117 polymorphism and lipid phenotypes.

• Lipid profiling: Multiple studies have identified significant associations between this SNP and elevated levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and non-HDL cholesterol.
• Allelic influence: While the specific "risk allele" can vary by population context, the G allele (and specifically the GG genotype) is frequently associated with higher levels of circulating cholesterol markers in many lipid-focused genomic studies.
• Population data: In specific cohorts, including Chinese and Thai populations, the variant has been documented as a modifier of lipid traits, contributing to the polygenic risk for elevated LDL-C.

Mechanistic explanations

The connection between the rs1367117 variant and particle burden is rooted in the fundamental biology of apolipoprotein B (apoB).

• Stoichiometry of particles: Every atherogenic lipoprotein—including very-low-density (VLDL), intermediate-density (IDL), and low-density (LDL) lipoproteins—contains exactly one molecule of apoB. Consequently, the concentration of plasma apoB is a direct surrogate for the total number of these potentially harmful particles.
• Gene function: Because the rs1367117 SNP is located within the APOB gene, it is mechanistically positioned to influence the assembly, secretion, or clearance rates of these lipoproteins. A genotype associated with higher LDL-C or apoB levels logically represents a higher "burden" of circulating atherogenic particles.
• Lipid metabolism: Variations in the APOB sequence can alter the stability of the protein or its interaction with LDL receptors, leading to longer residence times for LDL particles in the bloodstream and increasing the overall particle count.

Limitations and considerations

While the association is strong, there are nuances to consider regarding clinical application.

• Direct quantification: Most evidence relies on measured LDL-C and apoB mass rather than direct particle counts (NMR or ion mobility). However, apoB mass is widely accepted as a highly accurate proxy for particle number.
• Modifier status: This variant is typically viewed as a "modifier" of lipid levels rather than a primary cause of severe monogenic conditions like Familial Hypercholesterolemia. Its effect is often cumulative when combined with other genetic and lifestyle factors.

Bottom line

The claim that the APOB rs1367117 GG genotype is associated with higher LDL-C and a higher burden of apoB-containing particles is scientifically plausible. While direct particle-count studies for this specific SNP are limited, the established association with elevated LDL-C and the 1:1 ratio of apoB to atherogenic particles strongly support a tendency toward a higher particle burden in individuals carrying the risk-associated genotype.